Supplemental Fig S10 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

September 17, 2025

View at Publisher

Ask AI

Bookmark

Share

Key Points

Zilovertamab vedotin demonstrates a stable MMAE plasma concentration over time in metastatic solid tumors, indicating potential therapeutic efficacy.
The study tracked plasma concentration profiles of MMAE in participants administered Zilovertamab vedotin IV every three weeks, revealing consistent levels.
This phase 2 study employed intravenous infusions to assess the pharmacokinetics of MMAE—a critical component in targeting cancer cells.
The findings may pave the way for improved treatment protocols in managing metastatic solid tumors, highlighting the drug's potential.

Phase 2 trial evaluates plasma concentration of MMAE in participants with metastatic solid tumors, suggesting effective dosing.

Supplemental Fig S10. Plasma Conc. vs Time Profiles of MMAE in C1 Following Zilovertamab Vedotin IV Twice Every 3 Wks

No takes yet. Share an insight, caveat, or question.

Meric‐Bernstam et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share